Reuters logo
BRIEF-KemPharm strengthens ADHD prodrug pipeline with development of KP484
June 28, 2017 / 11:43 AM / 4 months ago

BRIEF-KemPharm strengthens ADHD prodrug pipeline with development of KP484

June 28 (Reuters) - KemPharm Inc

* KemPharm strengthens adhd prodrug pipeline with development of KP484, a new, super-extended release adhd methylphenidate product candidate

* KemPharm Inc - ‍KP415 end-of-phase 1 meeting with FDA affirms KemPharm’s development plan and potential NDA submission as early as late 2018​

* KemPharm Inc - Anticipates that it will initiate a human abuse liability (HAL) program of KP415 beginning in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below